Emerging therapeutics for ocular surface disease
Authors:
- 1 October 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 16 (5) , 477-486
Abstract
The present review provides an overview on the potential of different systemic and topical treatments in chronic forms of ocular allergy and dry eye disorder (DED). The impact on anterior surface of ocular inflammatory disorder encompasses an array of conditions, which are frequently underreported. This can contribute to underdiagnoses and ineffective management from healthcare providers such as an allergist and/or ophthalmologist who routinely provide care for these common disorders. Owing to the current limited therapeutic options, healthcare providers are routinely seeking alternative treatments that could facilitate effective management of the conditions. Recent advances in immunopathophysiology of ocular surface disorders has provided new potential targets and therapeutic strategies for the treatment of DED and ocular allergy that may include various immunobiological modulators. These modulators have focused on regulating the Th1 and Th2 immune-mediated inflammatory pathways that inhibit various cytokines (e.g. IL-1, IL-4, IL-5, IL-9, IL-13) antibodies (e.g. IgE), and other surface markers of various cell lines (e.g. activated T-lymphocytes, lymphocyte function-associated antigen-1). Recent findings about the pathophysiology of DED and ocular allergy have led to the greater understanding of the molecular and cellular mechanisms of ocular surface diseases leading to the potential novel targets for immunomodulation of anterior surface ocular disorders. New topical glucocorticoids, leukotriene receptor antagonists, IL-1 antagonists, IL-5, IL-4/IL-13 antagonists, integrin antagonists, and quinolone derivatives appear to be encouraging.Keywords
This publication has 37 references indexed in Scilit:
- Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye DiseaseThe Ocular Surface, 2016
- Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye DiseaseOphthalmology, 2015
- Pharmacoeconomics of anterior ocular inflammatory diseaseCurrent Opinion in Allergy and Clinical Immunology, 2013
- Immunomodulators for conjunctivitisCurrent Opinion in Allergy and Clinical Immunology, 2013
- Emerging therapies in allergic conjunctivitis and dry eye syndromeExpert Opinion on Pharmacotherapy, 2013
- The epidemiology of ocular and nasal allergy in the United States, 1988-1994Journal of Allergy and Clinical Immunology, 2010
- Emerging drugs for conjunctivitisExpert Opinion on Emerging Drugs, 2009
- Aplicaciones del suero autólogo en oftalmologíaArchivos de la Sociedad Española de Oftalmología, 2007
- Autologous serum eye drops for ocular surface disordersBritish Journal of Ophthalmology, 2004
- An Immunohistochemical Study of Topical Cyclosporine in Vernal KeratoconjunctivitisAmerican Journal of Ophthalmology, 1996